Uwe Jochen Dengler

Title: Uwe Jochen Dengler: Innovator in Alzheimer's Research

Introduction

Uwe Jochen Dengler is a notable inventor based in Loerrach, Germany. He has made significant contributions to the field of Alzheimer's research through his innovative work. His research focuses on the genetic factors associated with Alzheimer's Disease, aiming to identify potential therapeutic targets.

Latest Patents

Dengler holds a patent for "Transgenic Drosophila melanogaster expressing a β42 in the eye." This patent discloses transgenic flies that exhibit altered phenotypes due to the expression of the Abeta and C99 portions of the human APP gene. The patent also outlines the use of these flies in methods to identify genes and their human homologs that may be involved in Alzheimer's Disease. Furthermore, it discusses the potential of these human homologs as drug targets for developing therapeutics to treat Alzheimer's Disease and other conditions related to defects in the APP pathway. The patent includes pharmaceutical compositions comprising substances directed to these genes.

Career Highlights

Dengler is currently associated with Novartis Corporation, where he continues to advance his research in the field of genetics and neurodegenerative diseases. His work has garnered attention for its potential impact on understanding and treating Alzheimer's Disease.

Collaborations

Dengler collaborates with esteemed colleagues, including Dalia Cohen and Alyce Lynn Finelli, who contribute to his research endeavors.

Conclusion

Uwe Jochen Dengler's innovative work in Alzheimer's research highlights the importance of genetic studies in developing therapeutic strategies. His contributions through patents and collaborations continue to pave the way for advancements in understanding and treating this complex disease.